{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:24:40Z","timestamp":1789363480458,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cidjournal.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.clindermatol.2014.12.005","type":"journal-article","created":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T18:25:35Z","timestamp":1418063135000},"page":"289-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Systemic therapy of childhood atopic dermatitis"],"prefix":"10.1016","volume":"33","author":[{"given":"Nathaniel A.","family":"Slater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean S.","family":"Morrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2014.12.005_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/all.12270","article-title":"New insights into the epidemiology of childhood atopic dermatitis","volume":"69","author":"Flohr","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-0960.2008.00451_1.x","article-title":"Systemic therapy of paediatric atopic dermatitis: An update","volume":"49","author":"Borchard","year":"2008","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0015","first-page":"1158","article-title":"Management of severe atopic dermatitis in children","volume":"11","author":"Tan","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/adc.68.5.677","article-title":"Growth in atopic eczema","volume":"68","author":"Massarano","year":"1993","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1824-7288-37-59","article-title":"Quality of life measures in Italian children with atopic dermatitis and their families","volume":"37","author":"Monti","year":"2011","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0030","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7861\/clinmedicine.12-2-172","article-title":"Systemic treatment of adult atopic dermatitis","volume":"12","author":"Cookson","year":"2012","journal-title":"Clin Med"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/ACI.0b013e3283551da5","article-title":"Update on systemic therapies for atopic dermatitis","volume":"12","author":"Denby","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3 Pt 1","key":"10.1016\/j.clindermatol.2014.12.005_bb0040","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2004.11.022","article-title":"Infliximab in the treatment of moderate to severe atopic dermatitis","volume":"52","author":"Jacobi","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0045","first-page":"174","article-title":"Biologics in atopic dermatitis","volume":"10","author":"Ta\u00efeb","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0055","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1542\/peds.2007-2232","article-title":"Management of atopic dermatitis in the pediatric population","volume":"122","author":"Krakowski","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0060","series-title":"Atopic eczema in children","first-page":"CG57","author":"National Institute for Health and Clinical Excellence","year":"2007"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ced.12143","article-title":"What\u2019s new in atopic eczema? An analysis of systematic reviews published in 2010\u201311","volume":"38","author":"Torley","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0070","series-title":"Atopic eczema in children: Management of atopic eczema in children from birth up to the age of 12 years","author":"Excellence NI for H and C","year":"2007"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jaad.2006.05.073","article-title":"Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis","volume":"56","author":"Krejci-Manwaring","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0080","doi-asserted-by":"crossref","first-page":"774.e6","DOI":"10.1016\/j.jaci.2013.03.016","article-title":"Systemic therapies for severe atopic dermatitis in children and adults","volume":"132","author":"Flohr","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1939-4551-6-6","article-title":"Difficult to control atopic dermatitis","volume":"6","author":"Darsow","year":"2013","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0090","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3928\/00904481-20090622-08","article-title":"Systemic therapies for pediatric atopic dermatitis: A review for the primary care physician","volume":"38","author":"Shaw","year":"2009","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1525-1470.2011.01661.x","article-title":"Treatment outcomes of secondarily impetiginized pediatric atopic dermatitis lesions and the role of oral antibiotics","volume":"29","author":"Travers","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/all.12339","article-title":"Systemic therapy for atopic dermatitis","volume":"69","author":"Simon","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0105","first-page":"651","article-title":"PAPERS AND SHORT REPORTS Combined oral and nasal beclomethasone diproprionate in children with atopic eczema: A randomised controlled trial","volume":"289","author":"Heddle","year":"1984"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0110","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/0011-393X(95)85143-7","article-title":"A randomized, double-blind, placebo-controlled, crossover trial of systemic flunisolide in the treatment of children with severe atopic dermatitis","volume":"56","author":"La Rosa","year":"1995","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1651-2227.1994.tb18102.x","article-title":"Methylprednisolone bolus: A novel therapy for severe atopic dermatitis","volume":"83","author":"Galli","year":"1994","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00003495-200969030-00005","article-title":"Systemic therapy of atopic dermatitis in children","volume":"69","author":"Ricci","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2009.09561.x","article-title":"Prednisolone versus ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial","volume":"162","author":"Schmitt","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0301-0546(05)73248-1","article-title":"Rebound phenomenon to systemic corticosteroid in atopic dermatitis","volume":"33","author":"Forte","year":"2005","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0135","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1398-9995.2004.00639.x","article-title":"Cyclosporine treatment decreases the percentage of cutaneous lymphocyte antigen (CLA)(+)CD4(+) T cells in children with severe atopic dermatitis","volume":"59","author":"Lee","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0140","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/j.1398-9995.2009.02054.x","article-title":"Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis","volume":"64","author":"Brandt","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0145","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0190-9622(96)90281-9","article-title":"Cyclosporine in severe childhood atopic dermatitis: A multicenter study","volume":"34","author":"Berth-Jones","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2133.2000.03241.x","article-title":"Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy","volume":"142","author":"Harper","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0155","first-page":"139","article-title":"High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis","volume":"4","author":"Bemanian","year":"2005","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0160","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1468-3083.2006.02023.x","article-title":"Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis","volume":"21","author":"Schmitt","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/09546634.2012.672709","article-title":"Factors determining the effectiveness of oral ciclosporin in the treatment of severe childhood atopic dermatitis","volume":"23","author":"Beaumont","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0170","series-title":"Comprehensive dermatologic drug therapy [electronic resource]","author":"Wolverton","year":"2013"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0175","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2012.07.001","article-title":"Oral azathioprine for recalcitrant pediatric atopic dermatitis: Clinical response and thiopurine monitoring","volume":"68","author":"Caufield","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0185","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1525-1470.2011.01488.x","article-title":"Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil","volume":"28","author":"Waxweiler","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546630802512646","article-title":"Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults","volume":"20","author":"Hon","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0195","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","article-title":"Azathioprine in severe adult atopic dermatitis: A double-blind, placebo-controlled, crossover trial","volume":"147","author":"Berth-Jones","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0200","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: A double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0205","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1525-1470.2003.20617.x","article-title":"Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency","volume":"20","author":"Murphy","year":"2003","journal-title":"Pediatr Dermatol"},{"issue":"Pt 5","key":"10.1016\/j.clindermatol.2014.12.005_bb0210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0004563212473441","article-title":"Biological variation of thiopurine methyltransferase enzyme activity: When has a significant change taken place?","volume":"50","author":"Van Egmond","year":"2013","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2133.2007.07947.x","article-title":"Mycophenolate mofetil for severe childhood atopic dermatitis: Experience in 14 patients","volume":"157","author":"Heller","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0220","first-page":"870","article-title":"Mycophenolate mofetil is effective in the treatment of atopic dermatitis","volume":"137","author":"Grundmann-Kollmann","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0225","first-page":"23","article-title":"Mycophenolate mofetil therapy for moderate to severe atopic dermatitis","volume":"32","author":"Murray","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0230","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial","volume":"64","author":"Haeck","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0235","series-title":"Comprehensive Dermatologic Drug Therapy [electronic resource]","author":"Wolverton","year":"2013"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0240","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00431-012-1893-3","article-title":"Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: A multicenter experience from Egypt","volume":"172","author":"El-Khalawany","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0245","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0250","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cyto.2013.05.011","article-title":"Polydesensitisation with reducing elevated serum total IgE by IFN-gamma therapy in atopic dermatitis: IFN-gamma and polydesensitisation (PDS)","volume":"64","author":"Lee","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0255","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0190-9622(93)70026-P","article-title":"Recombinant interferon gamma therapy for atopic dermatitis","volume":"28","author":"Hanifin","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0260","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1067\/mjd.2000.104793","article-title":"Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma","volume":"42","author":"Jang","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0265","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1006\/cyto.1999.0589","article-title":"Pilot Study of Ifn-\u0393-Induced Specific Hyposensitization for House Dust Mites in Atopic Dermatitis: Ifn-\u0393-Induced Immune Deviation As a New Therapeutic Concept for Atopic Dermatitis","volume":"12","author":"Noh","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0270","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1525-1470.2011.01654.x","article-title":"Intravenous immunoglobulin to treat severe atopic dermatitis in children: A case series","volume":"29","author":"Turner","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0275","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.aller.2011.04.007","article-title":"Experience with intravenous immunoglobulin in severe childhood atopic dermatitis","volume":"40","author":"Ozen","year":"2012","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4168\/aair.2011.3.2.89","article-title":"Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis","volume":"3","author":"Jee","year":"2011","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0285","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1399-3038.2001.012003154.x","article-title":"Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: A pilot study","volume":"12","author":"Pei","year":"2001","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0290","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09546630510026328","article-title":"Brief case series: Montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis","volume":"16","author":"Hon","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0295","first-page":"232","article-title":"Montelukast treatment in children with moderately severe atopic dermatitis","volume":"39","author":"Ehlayel","year":"2007","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0300","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaad.2004.12.011","article-title":"Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial","volume":"53","author":"Veien","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0305","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/j.1365-2222.2007.02811.x","article-title":"A double-blind, placebo-controlled trial of montelukast in adult atopic eczema","volume":"37","author":"Friedmann","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0310","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: Depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0315","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2005.09.030","article-title":"Treatment of recalcitrant atopic dermatitis with omalizumab","volume":"54","author":"Lane","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0320","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2005.12.045","article-title":"Efficacy of anti-IgE therapy in patients with atopic dermatitis","volume":"55","author":"Vigo","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0325","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2230.2012.04438.x","article-title":"Anti-immunoglobulin E in the treatment of refractory atopic dermatitis","volume":"38","author":"Kim","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0330","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/all.12234","article-title":"Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines","volume":"69","author":"Hotze","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0335","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1468-3083.2011.04326.x","article-title":"Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases","volume":"26","author":"Toledo","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0340","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2005.02.014","article-title":"Failure of omalizumab for treatment of severe adult atopic dermatitis","volume":"53","author":"Krathen","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0345","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0350","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jaci.2011.09.009","article-title":"Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection","volume":"128","author":"Navarini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0355","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaad.2005.03.013","article-title":"Etanercept is minimally effective in 2 children with atopic dermatitis","volume":"53","author":"Buka","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0360","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archderm.142.5.555","article-title":"Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab","volume":"142","author":"Weinberg","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0365","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaad.2006.08.031","article-title":"Efalizumab for severe atopic dermatitis: A pilot study in adults","volume":"56","author":"Takiguchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0370","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1468-3083.2009.03202.x","article-title":"Efalizumab for severe refractory atopic eczema: Retrospective study on 11 cases","volume":"24","author":"Ibler","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0375","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0380","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaci.2008.03.007","article-title":"Anti-CD20 (rituximab) treatment for atopic eczema","volume":"121","author":"Sediv\u00e1","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0385","first-page":"190","article-title":"Sequential combined therapy with omalizumab and rituximab: A new approach to severe atopic dermatitis","volume":"23","author":"S\u00e1nchez-Ram\u00f3n","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0390","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1525-1470.2012.01850.x","article-title":"Update on the role of systemic vitamin D in atopic dermatitis","volume":"30","author":"Mutgi","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0395","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/all.12167","article-title":"Low vitamin D serum level is inversely associated with eczema in children and adolescents in Germany","volume":"68","author":"Heimbeck","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0400","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2013.01.010","article-title":"Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity","volume":"69","author":"Chiu","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0405","first-page":"1","article-title":"A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis","volume":"3","author":"Hata","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0410","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaad.2013.03.014","article-title":"Vitamin D effects in atopic dermatitis","volume":"69","author":"Samochocki","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0415","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","article-title":"Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: Results of a randomized, double-blind, placebo-controlled, multicentre trial","volume":"158","author":"Ruzicka","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0420","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2133.2009.09522.x","article-title":"Treatment of atopic eczema with oral alitretinoin","volume":"162","author":"Grahovac","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0425","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1468-3083.2010.03832.x","article-title":"Narrow band UVB: Is it effective and safe for paediatric psoriasis and atopic dermatitis?","volume":"25","author":"Pavlovsky","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0430","first-page":"28","article-title":"The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy","volume":"32","author":"Clayton","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.005_bb0435","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/ACI.0b013e32830fb8fd","article-title":"Novel immunologic approaches in the treatment of atopic eczema","volume":"8","author":"Belloni","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X14003046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X14003046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T18:35:14Z","timestamp":1717612514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X14003046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0738081X14003046"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2014.12.005","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy of childhood atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2014.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}